Research Topics
Species | A J MuirSummaryAffiliation: Duke University Medical Center Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Diagnosis and treatment of chronic hepatitis C infectionKeyur Patel
Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27707, USA
BMJ 332:1013-7. 2006
Reducing medication regimen complexity: a controlled trialA J Muir
Division of Gastroenterology, Duke University Medical Center, Durham, NC 27710, USA
J Gen Intern Med 16:77-82. 2001..To determine if a visual intervention (medication grid) delivered to physicians can reduce medication regimen complexity...
Telaprevir for the treatment of chronic hepatitis C infectionAndrew J Muir
Division of Gastroenterology and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27710, USA
Expert Rev Anti Infect Ther 9:1105-14. 2011..Viral resistance can develop during treatment with telaprevir, and patients will need to be educated on their role in adherence to minimize the risk of resistance and improve their chances of cure of HCV infection...
Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whitesAndrew J Muir
Division of Gastroenterology, Duke University, Durham, NC, USA
N Engl J Med 350:2265-71. 2004..The increased prevalence of infection with hepatitis C virus (HCV) genotype 1, which has a lower response rate than other genotypes, has been suggested as the cause...
Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infectionAndrew J Muir
Division of Gastroenterology, Duke University, Durham, NC 27701, USA
Hepatology 52:822-32. 2010....
Interferon gamma-1b for the treatment of fibrosis in chronic hepatitis C infectionA J Muir
Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
J Viral Hepat 13:322-8. 2006..These data provide a basis for further study of interferon gamma-1b in patients with chronic fibrosing liver disease...
A descriptive evaluation of eligibility for therapy among veterans with chronic hepatitis C virus infectionAndrew J Muir
Division of Gastroenterology, Duke University Medical Center, Durham, North Carolina 27710, USA
J Clin Gastroenterol 34:268-71. 2002..To assess the number of chronic hepatitis C patients eligible for therapy...
Hepatitis C treatment among racial and ethnic groups in the IDEAL trialA J Muir
Duke Clinical Research Institute and Division of Gastroenterology, Duke University Medical Center, Durham, NC 27701, USA
J Viral Hepat 18:e134-43. 2011..Therefore, decisions regarding HCV treatment should consider the predictive value of the early on-treatment response, not just baseline characteristics, such as race and ethnicity...
A survey of current liver biopsy practice patternsAndrew J Muir
Division of Gastroenterology, Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
J Clin Gastroenterol 35:86-8. 2002..To survey clinicians regarding current liver biopsy practice patterns...
Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment responseAndrew J Muir
Duke Clinical Research Institute and Division of Gastroenterology, Duke University Medical Center, Durham, NC 27715, USA
Hepatology 54:1538-46. 2011..CONCLUSION: This study demonstrated the benefit of retreatment with a telaprevir-based regimen for patients with well-characterized nonresponse (null and partial) or relapse to a prior course of PR treatment...
Telaprevir for previously treated chronic HCV infectionJohn G McHutchison
Duke Clinical Research Institute and Duke University Medical Center, Durham, NC, USA
N Engl J Med 362:1292-303. 2010..Patients with genotype 1 hepatitis C virus (HCV) who do not have a sustained response to therapy with peginterferon alfa and ribavirin have a low likelihood of success with retreatment...
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearanceDongliang Ge
Institute for Genome Sciences and Policy, Center for Human Genome Variation, Duke University, Durham, North Carolina 27708, USA
Nature 461:399-401. 2009....
Treatment of hepatitis C in special populationsMeera Ramamurthy
Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
Clin Liver Dis 10:851-65. 2006..These groups generally were not included in the early large clinical trials of HCV treatment. This article reviews recent findings in these patients groups and examines future directions...
Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virusAlexander J Thompson
Duke Clinical Research Institute, Durham, North Carolina, USA
Gastroenterology 139:120-9.e18. 2010..We sought to confirm the polymorphism's clinical relevance by intention-to-treat analysis evaluating on-treatment virologic response and SVR...
Severity of Clostridium difficile-associated diarrhea in solid organ transplant patientsZ F Gellad
Department of Medicine, Division of Gastroenterology, Duke University Medical Center, Durham, North Carolina 27710, USA
Transpl Infect Dis 9:276-80. 2007..Exposure to corticosteroids was significantly associated with an increased risk of relapse and may warrant a longer treatment course...
Gastroesophageal reflux and altered motility in lung transplant rejectionJ M Castor
Division of Gastroenterology, Department of Medicine, Duke University Medical Center, Durham, NC, USA
Neurogastroenterol Motil 22:841-50. 2010..The article will conclude with a discussion of the evaluation and management of patients undergoing lung transplantation at our center...
A case of electrical storm in a liver transplant patientT D Schmidt
Division of Gastroenterology, Duke University Medical Center, Durham, North Carolina 27710, USA
Transplant Proc 35:1437-8. 2003....
Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirinJeanette J McCarthy
Institute for Genome Sciences and Policy, Duke University Medical Center, Durham, North Carolina 27708, USA
Gastroenterology 138:2307-14. 2010..We investigated the association between the polymorphism rs12979860 and treatment response in a diverse cohort of chronic HCV patients...
Hepatitis C transmission, prevention, and treatment knowledge among patients with HIVRae Jean Proeschold-Bell
Duke University Global Health Institute and Duke University Center for Health Policy, Durham, NC 27708, USA
South Med J 103:635-41. 2010..Little is known about the HCV knowledge of PLWHA...
Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infectionJohn G McHutchison
Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA
N Engl J Med 361:580-93. 2009..Treatment guidelines recommend the use of peginterferon alfa-2b or peginterferon alfa-2a in combination with ribavirin for chronic hepatitis C virus (HCV) infection. However, these regimens have not been adequately compared...
Rates of surveillance and management of hepatocellular carcinoma in patients evaluated at a liver transplant centerJanice H Jou
Duke University Medical Center, Box 3913, Durham, NC 27710, USA
Dig Dis Sci 55:3591-6. 2010..We assessed if patients evaluated for hepatocellular carcinoma are being diagnosed by surveillance, the proportion of patients meeting Milan criteria at diagnosis, and rates of liver transplantation...
Uncertainty, symptoms, and quality of life in persons with chronic hepatitis CDonald E Bailey
Duke University School of Nursing, DUMC PO Box 3322, Durham, NC 27710, USA
Psychosomatics 50:138-46. 2009..Chronic hepatitis C (CHC) is the most common blood-borne infection in the United States, but little is known about illness uncertainty in these patients...
Disparities in liver transplantation before and after introduction of the MELD scoreCynthia A Moylan
Division of Gastroenterology, Duke University Medical Center, PO Box 3913, Durham, NC 27710, USA
JAMA 300:2371-8. 2008..Before MELD, black patients were more likely to die or become too sick to undergo liver transplantation compared with white patients. Little information exists regarding sex and access to liver transplantation...
De-novo cholangiocarcinoma in the setting of recurrent primary sclerosing cholangitis following liver transplantMichael A Heneghan
Division of Gastroenterology, Duke University Medical Center, Durham, NC, USA
Am J Transplant 3:634-8. 2003..No viable tumor was identified in the explanted liver. This case establishes that long-term complications associated with PSC and biliary-enteric surgery such as CCA may become apparent in new grafts post-transplant...
Frequency and predictors of de novo hepatocellular carcinoma in patients awaiting orthotopic liver transplantation during the model for end-stage liver disease eraCarla W Brady
Veterans Affairs Medical Center, Durham, NC, USA
Liver Transpl 14:228-34. 2008..06, 1.86) emerged as a predictor of increased odds of de novo HCC. A significant proportion of patients listed for OLT develop de novo HCC. Identifying predictors of HCC in these patients may facilitate timely HCC screening and diagnosis...
An examination of factors predicting prioritization for liver transplantationAndrew J Muir
Division of Gastroenterology, Duke University Medical Center, Durham, NC 27710, USA
Liver Transpl 8:957-61. 2002..In conclusion, these data show the wide range of practice patterns with the use of status 2A, and these findings suggest that certain patient groups might have received preference in the previous liver transplant allocation system...
Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infectionJohn G McHutchison
Duke Clinical Research Institute and Duke University, Durham, NC 27715, USA
N Engl J Med 360:1827-38. 2009..Telaprevir, a protease inhibitor specific to the HCV nonstructural 3/4A serine protease, rapidly reduced HCV RNA levels in early studies...
The use of mind-body medicine and prayer among adult patients with chronic hepatitis CJacqueline A Richmond
Gastroenterology Hepatology Research Program, Duke Clinical Research Institute, Durham, North Carolina, USA
Gastroenterol Nurs 33:210-6. 2010..To provide patient-centered healthcare, health providers need to be aware of the alternative support strategies, including mind-body medicine, used by patients...
Effect of donor age on survival of liver transplant recipients with hepatitis C virus infectionSteven L Condron
Division of Gastroenterology, Department of Medicine, Duke University Medical Center and Duke Clinical Research Institute, Durham, NC, USA
Transplantation 80:145-8. 2005..These factors should be considered when assessing OLT recipient and donor candidacy in patients with HCV...
Treatment of hepatitis C in special populationsCynthia A Moylan
Division of Gastroenterology and Duke Clinical Research Institute, Duke University Medical Center, Box 3913, Durham, NC 27710, USA
Clin Liver Dis 9:567-77, v. 2005..This article reviews recent findings from research in these patient groups and examines future directions and treatment trials...
Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infectionJosephine H Li
Institute for Genome Sciences and Policy, Durham, NC 27708, USA
Hepatology 51:1904-11. 2010....
ITPA gene variants protect against anaemia in patients treated for chronic hepatitis CJacques Fellay
Institute for Genome Sciences and Policy, Center for Human Genome Variation, Duke University, Durham, North Carolina 27708, USA
Nature 464:405-8. 2010..Here we show that genetic variants leading to inosine triphosphatase deficiency, a condition not thought to be clinically important, protect against haemolytic anaemia in hepatitis-C-infected patients receiving RBV...
Clinical utilization of digital rectal examination and fecal occult blood testing upon hospital admissionCharles D Scales
Division of Gastroenterology, Department of Medicine, Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
J Clin Gastroenterol 40:913-8. 2006..Follow-up evaluation of positive FOBT in the absence of GI bleeding symptoms was very low. Low utilization and follow-up rates may limit the utility of admission DRE with FOBT for cancer screening...
Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reductionAlexander J Thompson
Duke Clinical Research Institute, Durham, North Carolina 27715, USA
Gastroenterology 139:1181-9. 2010..We aimed to replicate this finding in an independent cohort from the Study of Viral Resistance to Antiviral Therapy of Chronic Hepatitis C and to investigate the effects of these variants beyond week 4...
Utility of thiopurine methyltransferase genotyping and phenotyping, and measurement of azathioprine metabolites in the management of patients with autoimmune hepatitisMichael A Heneghan
Department of Gastroenterology, Duke University Medical Center, Durham, NC 27710, USA
J Hepatol 45:584-91. 2006..Our aims were to evaluate the role of TPMT genotyping and phenotyping and to examine 6-TG and 6-MMP metabolite levels in patients with AIH...
Growth factors during HCV therapy may be "cost-effective", but are they "effective"?Andrew J Muir
Hepatology 44:1400-3. 2006
Erythropoietic response to anemia in chronic hepatitis C patients receiving combination pegylated interferon/ribavirinVijayan Balan
Division of Transplantation Medicine, Mayo Clinic Hospital, 5777 E. Mayo Boulevard, Phoenix, AZ 85054, USA
Am J Gastroenterol 100:299-307. 2005..CONCLUSIONS: HCV-infected patients receiving PEG-IFN/RBV therapy have reductions in Hb, platelets, and WBCs, possibly due to bone marrow suppression. They also have diminished endogenous sEPO production for their degree of anemia...
Acute HCV: the early bird catches the virusAndrew J Muir
Gastroenterology 122:1176-7; discussion 1177-8. 2002
Validation of a simple predictive model for the identification of mild hepatic fibrosis in chronic hepatitis C patientsKeyur Patel
Hepatology 37:1222; author reply 1222-3. 2003
Ribavirin as maintenance therapy for hepatitis C patients: an interim peacekeeper?Keyur Patel
Hepatology 38:21-4. 2003
HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosisCarla W Brady
Hepatology 42:496-7; author reply 497. 2005
Using capsule endoscopy to identify GI tract lesions in cirrhotic patients with portal hypertension and chronic anemiaKaren R Canlas
Division of Gastroenterology and Hepatology, Duke University Medical Center, Durham, NC 27705, USA
J Clin Gastroenterol 42:844-8. 2008..We aimed to evaluate the ability of capsule endoscopy (CE) to detect small intestine (SI) lesions, especially SI varices, in patients with intrahepatic cirrhosis, portal hypertension (PHTN), and chronic anemia...
In the clinic. Hepatitis CJanice H Jou
Ann Intern Med 148:ITC6-1-ITC6-16. 2008
Research Grants
- Interferon-gamma To Treat Chronic HCV InfectionAndrew Muir; Fiscal Year: 2002..Secondary endpoints include the biochemical response, inflammatory and regulatory cytokine levels, and quality of life during treatment. ..
